Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $103.88 Average PT from Analysts

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) have received a consensus rating of “Buy” from the twenty-one analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, sixteen have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $111.3529.

A number of research analysts have recently issued reports on RVMD shares. Royal Bank Of Canada boosted their price target on shares of Revolution Medicines to $165.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Truist Financial started coverage on shares of Revolution Medicines in a research note on Monday, May 18th. They set a “buy” rating and a $179.00 price target on the stock. Sanford C. Bernstein started coverage on shares of Revolution Medicines in a research note on Thursday. They set a “market perform” rating and a $151.00 price target on the stock. Finally, Wedbush boosted their price target on shares of Revolution Medicines to $165.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th.

Insider Buying and Selling at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 120,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $150.09, for a total transaction of $18,010,800.00. Following the transaction, the insider directly owned 276,698 shares in the company, valued at $41,529,602.82. The trade was a 30.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Margaret A. Horn sold 4,583 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the transaction, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 184,592 shares of company stock valued at $24,499,532. Insiders own 8.20% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

A number of large investors have recently made changes to their positions in RVMD. Meeder Advisory Services Inc. grew its position in Revolution Medicines by 3.0% during the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after buying an additional 120 shares during the period. PNC Financial Services Group Inc. grew its position in Revolution Medicines by 1.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock worth $802,000 after buying an additional 125 shares during the period. Deutsche Bank AG grew its position in Revolution Medicines by 0.4% during the fourth quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock worth $2,566,000 after buying an additional 130 shares during the period. Signaturefd LLC grew its position in Revolution Medicines by 33.1% during the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after buying an additional 163 shares during the period. Finally, Allworth Financial LP grew its position in Revolution Medicines by 57.2% during the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after buying an additional 210 shares during the period. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $151.56 on Friday. The company has a 50-day simple moving average of $123.75 and a 200-day simple moving average of $101.21. Revolution Medicines has a one year low of $34.00 and a one year high of $156.25. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. The stock has a market capitalization of $32.22 billion, a price-to-earnings ratio of -21.44 and a beta of 1.41.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, May 6th. The company reported ($2.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same quarter last year, the firm earned ($1.13) EPS. On average, analysts predict that Revolution Medicines will post -7.75 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.